Emerging treatments for depression

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 17, 2006, Pages 2323-2339

  Holtzheimer III, Paul E ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant treatment; Depression; Focal brain stimulation; Neuropsychopharmacology

Indexed keywords

3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; AGOMELATINE; AMANTADINE; ANTIDEPRESSANT AGENT; APREPITANT; ATYPICAL ANTIPSYCHOTIC AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; GLUCOCORTICOID RECEPTOR ANTAGONIST; KETAMINE; L 759274; MIANSERIN; MIFEPRISTONE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEFAZODONE; NEUROKININ 1 RECEPTOR ANTAGONIST; OMEGA 3 FATTY ACID; PLACEBO; REBOXETINE; RILUZOLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TIANEPTINE; TRAZODONE; UNINDEXED DRUG;

AGITATION; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FOOD; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HUMAN; INSOMNIA; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MAGNETOTHERAPY; META ANALYSIS; MONOAMINERGIC NERVE; NAUSEA; NEUROBIOLOGY; NEUROIMAGING; NEUROMODULATION; NONHUMAN; PRIAPISM; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TRANQUILIZING ACTIVITY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT FAILURE; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSION; ELECTROCONVULSIVE THERAPY; EXPERT TESTIMONY; HUMANS; PSYCHOTHERAPY;

EID: 33751572755     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.17.2323     Document Type: Review

References (200)

1. KESSLER RC, BERGLUND P, DEMLER O et al.: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62(6):593-602.
2. MURRAY CJL, LOPEZ AD: The Global Burden of Disease. MURRAY CJL, LOPEZ AD (Eds). Harvard University Press, Boston (1996).
3. FAVA M: Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry (2003) 53(8):649-659.
4. TRIVEDI MH, RUSH AJ, WISNIEWSKI SR et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry (2006) 163(1):28-40.
5. RUSH AJ, TRIVEDI MH, WISNIEWSKI SR et al.: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. (2006) 354(12):1231-1242.
6. SACKEIM HA: The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry (2001) 62 (Suppl.16):10-17.
7. ARROLL B, MACGILLIVRAY S, OGSTON S et al.: Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam. Med (2005) 3(5):449-456.
8. KRISHNAN KR: Monoamine Oxidase Inhibitors. In: Textbook of Psychopharmacology. Schatzberg AF et al. (Eds). The American Psychiatric Press, Inc., Washington, DC (1998):239-249.
9. TOLLEFSON GD, ROSENBAUM JF: Selective Serotonin Reuptake Inhibitors. In: Textbook of Psychopharmacology. Schatzberg AF et al. (Eds) The American Psychiatric Press, Inc., Washington, DC (1998):219-238.
10. THASE ME, ENTSUAH AR, RUDOLPH RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry (2001) 178:234-241.
11. DETKE MJ, WILTSE CG, MALLINCKRODT CH et al.: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. (2004) 14(6):457-470.
12. ALLGULANDER C, HACKETT D, SALINAS E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry (2001) 179:15-22.
13. GELENBERG AJ, LYDIARD RB, RUDOLPH RL et al.: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA (2000) 283(23):3082-3088.
14. THASE ME, HAIGHT BR, RICHARD N et al: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J. Clin. Psychiatry (2005) 66(8):974-981.
15. FAWCETT J, BARKIN RL: A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J. Clin. Psychiatry (1998) 59(3):123-127.
16. KELLER MB, MCCULLOUGH JP, KLEIN DN et al.: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N. Engl. J. Med. (2000) 342(20): 1462-1470.
17. ARANDA-MICHEL J, KOEHLER A, BEJARANO PA et al.: Nefazodone-induced liver failure: report of three cases. Ann. Intern. Med. (1999) 130(4 Pt 1):285-288.
18. MENDELSON WB: A review of the evidence for the efficacy and safety of trazodone in insomnia. J. Clin. Psychiatry (2005) 66(4):469-476.
19. BUTLER AC, CHAPMAN JE, FORMAN EM, BECK AT: The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin. Psychol. Rev. (2006) 26(1):17-31.
20. BECK AT: The current state of cognitive therapy: a 40-year retrospective. Arch. Gen. Psychiatry (2005) 62(9):953-959.
21. DE MELLO MF, DE JESUS MARI J, BACALTCHUK J, VERDELI H, NEUGEBAUER R. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur. Arch. Psychiatry Clin. Neurosci. (2005) 255(2):75-82.
22. ROFFMAN JL, MARCI CD, GLICK DM, DOUGHERTY DD, RAUCH SL: Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol. Med. (2005) 35(10):1385-1398.
23. GOLDAPPLE K, SEGAL Z, GARSON C et al.: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch. Gen. Psychiatry (2004) 61(1):34-41.
24. CONTE HR, PLUTCHIK R, WILD KV, KARASU TB: Combined psychotherapy and pharmacotherapy for depression. A systematic analysis of the evidence. Arch. Gen. Psychiatry (1986) 43(5):471-479.
25. SCHATZBERG AF, RUSH AJ, ARNOW BA et al.: Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch. Gen. Psychiatry (2005) 62(5):513-520.
26. NEMEROFF CB, HEIM CM, THASE ME et al.: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc. Natl. Acad. Sci. USA (2003) 100(24):14293-14296.
27. THE UK ECF REVIEW GROUP: Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet (2003) 361(9360):799-808.
28. FINK M: Convulsive therapy: a review of the first 55 years. J. Affect. Disord. (2001) 63(1-3):1-15.
29. SACKEIM HA, ROSS FR, HOPKINS N, CALEV L, DEVANAND DP: Subjective Side Effects Acutely Following ECT: Associations with Treatment Modality and Clinical Response. Convuls. Ther. (1987) 3(2):100-110.
30. BAKEWELL CJ, RUSSO J, TANNER C, AVERY DH, NEUMAIER JF: Comparison of clinics] efficacy and side effects for bitemporal and bifrontal electrode placement in electroconvulsive therapy. J. Ect. (2004) 20(3):145-153.
31. SACKEIM HA, HASKETT RF, MULSANT BH et al.: Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA (2001) 285(10):1299-1307.
32. NEMEROFF CB, BISSETTE G, AKIL H, FINK M: Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br. J. Psychiatry (1991) 158:59-63.
33. WAHLUND B, VON ROSEN D: ECT of major depressed patients in relation to biological and clinical variables: a brief overview. Neuropsychopharmacology (2003) 28 (Suppl. 1):S21-S26.
34. MANN JJ, AARONS SF, WILNER PJ et al.: A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry (1989) 46(1):45-50.
35. WECKER L, JAMES S, COPELAND N, PACHECO MA: Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol. Psychiatry (2003) 54(10):1099-1104.
36. AMSTERDAM JD: A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J. Clin. Psychiatry (2003) 64(2):208-214.
37. BODKIN JA, AMSTERDAM JD: Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am. J. Psychiatry (2002) 159(11):1869-1875.
38. DAILLY E, CHENU F, RENARD CE, BOURIN M: Dopamine, depression and antidepressants. Fundam. Clin. Pharmacol. (2004) 18(6):601-607.
39. ELHWUEGI AS: Central monoamines and their role in major depression. Prog. Neuropsychopharmacol Biol. Psychiatry (2004) 28(3):435-451.
40. PANIA L, GESSAB GL: Dopaminergic deficit and mood disorders. Int. Clin. Psychopharmacol. (2002) 17 (Suppl. 4):S1-S7.
41. NIERENBERG AA, DOUGHERTY D, ROSENBAUM JF: Dopaminergic agents and stimulants as antidepressant augmentation strategies. J. Clin. Psychiatry (1998) 59(Suppl. 5):60-64.
42. SKOLNICK P, POPIK P, JANOWSKY A, BEER B, LIPPA AS: Antidepressant-like actions of DOV 21,947: a 'triple' reuptake inhibitor. Eur. J. Pharmacol. (2003) 461(2-3):99-104.
43. SKOLNICK P, POPIK P, JANOWSKY A, BEER B, LIPPA AS: 'Broad spectrum' antidepressants: is more better for the treatment of depression? Life Sci. (2003) 73(25):3175-3179.
44. BEER B, STARK J, KRIETER P et al.: DOV 216,303, a 'triple' reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J. Clin. Pharmacol. (2004) 44(12):1360-1367.
45. MELTZER HY: The mechanism of novel antipsychotic drugs. Schizophr. Bull. (1991) 17(2):263-287.
46. MEYER JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry (2002) 63(5):425-433.
47. BYSTRITSKY A, ACKERMAN DL, ROSEN RM et al.: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J. Clin. Psychiatry (2004) 65(4):565-568.
48. CONNOR KM, PAYNE VM, GADDE KM, ZHANG W, DAVIDSON JR: The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J. Clin. Psychiatry (2005) 66(1):49-51.
49. BOGAN AM, KORAN LM, CHUONG HW, VAPNIK T, BYSTRITSKY A: Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J. Clin. Psychiatry (2005) 66(1):73-79.
50. HAMNER MB, DEITSCH SE, BRODRICK PS, ULMER HG, LORBERBAUM JP: Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J. Clin. Psychopharmacol. (2003) 23(1):15-20.
51. BARTZOKIS G, LU PH, TURNER J, MINTZ J, SAUNDERS CS: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol. Psychiatry (2005) 57(5):474-479.
52. STEIN MB, KLINE NA, MATLOFF JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am. J. Psychiatry (2002) 159(10):1777-1779.
53. THASE ME: What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry (2002) 63(2):95-103.
54. WORTHINGTON JJ, 3RD, KINRYS G, WYGANT LE, POLLACK MH: Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol. (2005) 20(1):9-11.
55. PAPAKOSTAS GI, PETERSEN TJ, NIERENBERG AA et al.: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry (2004) 65(2):217-221.
56. HIROSE S, ASHBY CR, Jr.: An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J. Clin. Psychiatry (2002) 63(8):733-736.
57. GUTMAN DA, OWENS MJ, NEMEROFF CB: Corticotropin-releasing factor receptor and glucocorticoid receptor antagonists: new approaches to antidepressant treatment. In: Current and Future Developments in Psychopharmacology. Den Boer JA et al. (Eds) Benecke, N.I., Amsterdam (2005):133-158.
58. ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CE: The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. (1999) 160(1):1-12.
59. VEITH RC, LEWIS N, LANGOHR JI et al.: Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res. (1993) 46(1):1-8.
60. DAUTZENBERG FM, HAUGER RL: The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. (2002) 23(2):71-77.
61. ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. (2000) 34(3):171-181.
62. WOLKOWITZ OM, REUS VI: Treatment of depression with antiglucocorticoid drugs. Psychosom. Med. (1999) 61(5):698-711.
63. MURPHY BE, FILIPINI D, GHADIRIAN AM: Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J. Psychiatry Neurosci. (1993) 18(5):209-213.
64. BELANOFF JK, KALEHZAN M, SUND B, FLEMING FICEK SK, SCHATZBERG AF: Cortisol activity and cognitive changes in psychotic major depression. Am. J. Psychiatry (2001) 158(10):1612-1616.
65. BELANOFF JK, FLORES BH, KALEZHAN M, SUND B, SCHATZBERG AF: Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. (2001) 21(5):516-521.
66. BELANOFF JK, ROTHSCHILD AJ, CASSIDY F et al.: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry (2002) 52(5):386-392.
67. KU YH, TAN L, LI LS, DING X: Role of corticotropin-releasing factor and substance P in pressor responses of nuclei controlling emotion and stress. Peptides (1998) 19(4):677-682.
68. BITTENCOURT JC, BENOIT R, SAWCHENKO PE: Distribution and origins of substance P-immunoreactive projections to the paraventricular and supraoptic nuclei: partial overlap with ascending catecholaminergic projections. J. Chem. Neuroanat. (1991) 4(1):63-78.
69. MAGOUL R, DUBOURG P, BENJELLOUN W, TRAMU G: Synaptic inputs of tachykinin-containing nerve terminals to target tyrosine-hydroxylase-, beta-endorphin- and neuropeptide Y-producing neurons of the arcuate nucleus. Double pre-embedding immunocytochemical study in the rat. J. Chem. Neuroanat. (1993) 6(6):419-429.
70. PELLETIER C, STEINBUSCH HW, VERHOFSTAD AA: Immunoreactive substance P and serotonin present in the same dense-core vesicles. Nature (1981) 293(5827):71-72.
71. HELKE CJ, YANG L: Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems. Ann. NY Acad. Sci. (1996) 780:185-192.
72. CULMAN J, UNGER T: Central tachykinins: mediators of defence reaction and stress reactions. Can. J. Physiol. Pharmacol. (1995) 73(7):885-891.
73. HELKE CJ, KRAUSE JE, MANTYH PW, COUTURE R, BANNON MJ: Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. Faseb J. (1990) 4(6):1606-1615.
74. KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281(5383):1640-1645.
75. CULMAN J, KLEE S, OHLENDORF C, UNGER T: Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J. Pharmacol. Exp. Ther. (1997) 280(1):238-246.
76. GERACIOTI TD, CARPENTER L, OWENS MJ et al.: Elevated cerebrospinal fluid substance P concentrations in post-traumatic stress disorder and major depression. Am. J. Psychiatry (2006)163(4):637-643 in press.
77. BONDY B, BAGHAI TC, MINOV C et al.: Substance P serum levels are increased in major depression: preliminary results. Biol. Psychiatry (2003) 53(6):538-542.
78. KELLER M, MONTGOMERY S, BALL W et al.: Lack of efficacy of substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry (2006) 59(3):216-223.
79. KRAMER MS, WINOKUR A, KELSEY J et al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology (2004) 29(2):385-392.
80. HERPFER I, LIEB K: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs (2005) 19(4):275-293.
81. FURMARK T, APPEL L, MICHELGARD A et al.: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonists GR205171, citalopram, or placebo. Biol. Psychiatry (2005) 58(2):132-142.
82. PAUL IA, SKOLNICK P: Glutamate and depression: clinical and preclinical studies. Ann. NY Acad. Sci. (2003) 1003:250-272.
83. ZARATE CA, JR., DU J, QUIROZ J et al.: Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann. NY Acad. Sci. (2003) 1003:273-291.
84. MCEWEN BS: Stress and hippocampal plasticity. Ann. Rev. Neurosci. (1999) 22:105-122.
85. SAPOLSKY RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol. Psychiatry (2000) 48(8):755-765.
86. ROGOZ Z, SKUZA G, MAJ J, DANYSZ W: Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology (2002) 42(8):1024-l030.
87. ROGOZ Z, SKUZA G, KUSMIDER M et al.: Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol. J. Pharmacol. (2004) 56(2):179-185.
88. STRYJER R, STROUS RD, SHAKED G et al.: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol. (2003) 18(2):93-96.
89. PALUCHA A, BRANSKI P, SZEWCZYK B et al.: Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol. Biochem. Behav. (2005) 81(4):901-906.
90. PILC A, KLODZINSKA A, BRANSKI P et al.: Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology (2002) 43(2):181-187.
91. LI X, WITKIN JM, NEED AB, SKOLNICK P: Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell. Mol. Neurobiol. (2003) 23(3):419-430.
92. OSTROFF R, GONZALES M, SANACORA G: Antidepressant effect of ketamine during ECT. Am. J. Psychiatry (2005) 162(7):1385-1386.
93. ZABATE CA, JR., SINGH JB, CARLSON PJ et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry (2006) 63(8):856-864.
94. ZARATE CA, JR., PAYNE JL, QUIROZ J et al.: An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry (2004) 161(1):171-174.
95. ZARATE CA, JR., QUIROZ JA, SINGH JB et al.: An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry (2005) 57(4):430-432.
96. PARKER G, GIBSON NA, BROTCHIE H et al.: Omega-3 fatty acids and mood disorders. Am. J. Psychiatry (2006) 163(6):969-978.
97. HAKKARAINEN R, PARTONEN T, HAUKKA J et al.: Is low dietary intake of omega-3 fatty acids associated with depression? Am. J. Psychiatry (2004) 161(3):567-569.
98. PEET M: Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot. Essent. Fatty Acids (2003) 69(6):477-485.
99. OSHER Y, BERSUDSKY Y, BELMAKER RH: Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J. Clin. Psychiatry (2005) 66(6):726-729.
100. NEMETS B, STAHL Z, BELMAKER RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry (2002) 159(3):477-479.
101. SU KP, HUANG SY, CHIU CC, SHEN WW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. (2003) 13(4):267-271.
102. STOLL AL, SEVERUS WE, FREEMAN MP et al.: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (1999) 56(5):407-412.
103. SILVERS KM, WOOLLEY CC, HAMILTON FC, WATTS PM, WATSON RA: Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot. Essent. Fatty Acids (2005) 72(3):211-218.
104. KECK PE, JR., MINTZ J, MCELROY SL et al.: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol. Psychiatry (2006) (in press)
105. MARANGELL LB, MARTINEZ JM, ZBOYAN HA et al.: A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry (2003) 160(5):996-998.
106. SRINIVASAN V, SMITS M, SPENCE W et al.: Melatonin in mood disorders. World J Biol. Psychiatry (2006) 7(3):138-151.
107. LEWY AJ, BAUER VK, CUTLER NL, SACK RL: Melatonin treatment of winter depression: a pilot study. Psychiatry Res. (1998) 77(1):57-61.
108. DOLBERG OT, HIRSCHMANN S, GRUNHAUS L: Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry (1998) 155(8):1119-1121.
109. 2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. (2002) 17(5):239-247.
110. KENNEDY SH, EMSLEY R: Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. (2006) 16(2):93-100.
111. MAYBERG HS: Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. Bull. (2003) 65:193-207.
112. BEN-MENACHEM E: Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol. (2002) 1(8):477-482.
113. BEN-MENACHEM E: Vagus nerve stimulation, side effects, and long-term safety. J. Clin. Neurophysiol. (2001) 18(5):415-418.
114. RUSH AJ, MARANGELL LB, SACKEIM HA et al.: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol. Psychiatry (2005) 58(5):347-354.
115. GEORGE MS, RUSH AJ, SACKEIM HA, MARANGELL LB: Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders. Int. J Neuropsychopharmacol. (2003) 6(1):73-83.
116. HARDEN CL, PULVER MC, RAVDIN LD et al.: A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav. (2000) 1(2):93-99.
117. ELGER G, HOPPE C, FALKAI P, RUSH AJ, ELGER CE: Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res. (2000) 42(2-3):203-210.
118. SACKEIM HA, RUSH AJ, GEORGE MS et al.: Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects and predictors of outcome. Neuropsychopharmacology (2001) 25(5):713-728.
119. NAHAS Z, MARANGELL LB, HUSAIN MM et al.: Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J. Clin. Psychiatry (2005) 66(9):1097-1104.
120. MARANGELL LB, RUSH AJ, GEORGE MS et al.: Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol. Psychiatry (2002) 51(4):280-287.
121. RUSH AJ, SACKEIM HA, MARANGELL LB et al.: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol. Psychiatry (2005) 58(5):355-363.
122. GEORGE MS, RUSH AJ, MARANGELL LB et al.: A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol. Psychiatry (2005) 58(5):364-373.
123. CORCORAN CD, THOMAS P, PHILLIPS J, O'KEANE V: Vagus nerve stimulation in chronic treatment-resistant depression: preliminary findings of an open-label study. Br. J. Psychiatry (2006) 189:282-283 in press.
124. NEMEROFF CB, MAYBERG HS, KRAHL SE et al.: VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology (2006) (in press)
125. CHAE JH, NAHAS Z, LOMAREV M et al.: A review of functional neuroimaging studies of vagus nerve stimulation (VNS). J. Psychiatr. Res. (2003) 37(6):443-455.
126. ZHANG Y, MCGUIRE M, WHITE DP, LING L: Serotonin receptor subtypes involved in vagus nerve stimulation-induced phrenic long-term facilitation in rats. Neurosci. Lett. (2004) 363(2):108-111.
127. BEN-MENACHEM E, HAMBERGER A, HEDNER T et al.: Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epilepsy Res. (1995) 20(3):221-227.
128. GROVES DA, BOWMAN EM, BROWN VJ: Recordings from the rat locus coeruleus during acute vagal nerve stimulation in the anaesthetised rat. Neurosci. Lett. (2005) 379(3):174-179.
129. LECHNER SM, CURTIS AL, BRONS R, VALENTINO RJ: Locus coeruleus activation by colon distention: role of corticotropin-releasing factor and excitatory amino acids. Brain Res. (1997) 756(1-2):114-124.
130. HASSERT DL, MIYASHITA T, WILLIAMS CL: The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala. Behav. Neurosci. (2004) 118(1):79-88.
131. KRAHL SE, CLARK KB, SMITH DC, BROWNING RA: Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia (1998) 39(7):709-714.
132. CARPENTER LL, MORENO FA, KLING MA et al.: Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biol.Psychiatry (2004) 56(6):418-426.
133. A receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy. Epilepsy Res. (2003) 55(1-2):59-70.
134. KRAHL SE, SENANAYAKE SS, PEKARY AE, SATTIN A: Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J. Psychiatr. Res. (2004) 38(3):237-240.
135. ANAND S, HOTSON J: Transcranial magnetic stimulation: neurophysiological applications and safety. Brain Cogn. (2002) 50(3):366-386.
136. PASCUAL-LEONE A, VALLS-SOLE J, WASSERMANN EM, HALLETT M: Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain (1994) 117(Pt 4):847-858.
137. CHEN R, CLASSEN J, GERLOFF C et al.: Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology (1997) 48(5):1398-1403.
138. HOFLICH G, KASPER S, HUFNAGEL A, RUHRMANN S, MOLLER H: Application of transcranial magnetic stimulation in treatment of drug-resistant major depression- a report of two cases. Human Psychopharmacology (1993) 8:361-365.
139. HOLTZHEIMER PE III, RUSSO J, AVERY DH: A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol. Bull. (2001) 35(4):149-169. Erratum in: Psychopharmacol Bull. (2003) 2037:2005.
140. BURT T, LISANBY SH, SACKEIM HA: Neuropsychiatric applications of transcranial magnetic stimulation: a meta-analysis. Int. J. Neuropsychopharmacol. (2002) 5(1):73-103.
141. KOZEL FA, GEORGE MS: Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. Journal of Psychiatric Practice (2002) 8(5):270-275.
142. MARTIN JL, BARBANOJ MJ, SCHLAEPFER TE et al.: Repetitive transcranial magnetic stimulation for the treatment of depression: systematic review and meta-analysis. Br. J. Psychiatry (2003) 182:480-491.
143. KLEIN E, KREININ I, CHISTYAKOV A et al.: Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch. Gen. Psychiatry (1999) 56(4):315-320.
144. FITZGERALD PB, BROWN TL, MARSTON NA et al.: Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (2003) 60(10):1002-1008.
145. JANUEL D, DUMORTIER G, VERDON CM et al.: A double-blind sham controlled study of right prefrontal repetitive transcranial magnetic stimulation (rTMS): therapeutic and cognitive effect in medication free unipolar depression during 4 weeks. Prog Neuropsychopharmacol Biol. Psychiatry (2006) 30(1):126-130.
146. ROSSINI D, LUCCA A, ZANARDI R, MAGRI L, SMERALDI E: Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res. (2005) 137(1-2):1-10.
147. SCHLAEPFER TE, KOSEL M, NFMEROFF CB: Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Affective Disorders. Neuropsychopharmacology (2003) 28(2):201-205.
148. GERSHON AA, DANNON PN, GRUNHAUS L: Transcranial magnetic stimulation in the treatment of depression. Am. J. Psychiatry (2003) 160(5):835-845.
149. HOLTZHEIMER PE, AVERY D, SCHLAEPFER TE: Antidepressant effects of repetitive transcranial magnetic stimulation. Br. J. Psychiatry (2004) 184:541-542.
150. AVERY DH, HOLTZHEIMER PE III, FAWAZ W et al.: A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol. Psychiatry (2006) 59(2):187-194.
151. GRUNHAUS L, DANNON PN, SCHREIBER S et al.: Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusionai major depressive disorder: an open study. Biol. Psychiatry (2000) 47(4):314-324.
152. GRUNHAUS L, SCHREIBER S, DOLBERG OT, POLAK D, DANNON PN: A randomized controlled comparison of electroconvulsive therapy and repetitive transcraniai magnetic stimulation in severe and resistant nonpsychotic major depression. Biol. Psychiatry (2003) 53(4):324-331.
153. JANICAK PG, DOWD SM, MARTIS B et al.: Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Biol. Psychiatry (2002) 51(8):659-667.
154. PRIDMORE S, BRUNO R, TURNIER-SHEA Y, REID P, RYBAK M: Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECF treatment sessions in major depressive episode. Int. J. Neuropsychopharmacol. (2000) 3(2):129-134.
155. POST A, KECK ME: Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms? J. Psychiatr. Res. (2001) 35(4):193-215.
156. MULLER MB, TOSCHI N, KRESSE AE, POST A, KECK ME: Long-term repetitive transcranial magnetic stimulation increases the expression of brain-derived neurotrophic factor and cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain. Neuropsychopharmacology (2000) 23(2):205-215.
157. KANNO M, MATSUMOTO M, TOGASHI H, YOSHIOKA M, MANO Y: Effects of acute repetitive transcranial magnetic stimulation on dopamine release in the rat dorsolateral striatum. J. Neurol. Sci. (2004) 217(1):73-81.
158. OHNISHI T, HAYASHI T, OKABE S et al.: Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex: an [11C]raclopride positron emission tomography study in anesthetized macaque monkeys. Biol. Psychiatry (2004) 55(5):484-489.
159. STRAFELLA AP, PAUS T, FRARACCIO M, DAGHER A: Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain (2003) 126 (Pt 12):2609-15.
160. ZANGEN A, HYODO K: Transcranial magnetic stimulation induces increases in extracellular levels of dopamine and glutamate in the nucleus accumbens. Neuroreport (2002) 13(18):2401-2405.
161. KECK ME, WELT T, MULLER MB et al.: Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology (2002) 43(1):101-109.
162. STRAFELLA AP, PAUS T, BARRETT J, DAGHER A: Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J. Neurosci. (2001) 21(15):RC157.
163. BEN-SHACHAR D, GAZAWI H, RIBOYAD-LEVIN J, KLEIN E: Chronic repetitive transcranial magnetic stimulation alters beta- adrenergic and 5-HT2 receptor characteristics in rat brain. Brain Res. (1999) 816(1):78-83.
164. SPEER AM, KIMBRELL TA, WASSERMANN EM et al.: Opposite effects of high- and low- frequency rTMS on regional brain activity in depressed patients. Biol. Psychiatry (2000) 48(12):1133-1141.
165. NADEAU SE, MCCOY KJ, CRUCIAN GP et al.: Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol. Behav. Neurol. (2002) 15(3):159-175.
166. MOTTAGHY FM, KELLER CE, GANGITANO M et al.: Correlation of cerebral blood flow and treatment effects of repetitive transcranial magnetic stimulation in depressed patients. Psychiatry Res. (2002) 115(1-2):1-14.
167. NAHAS Z, LOMAREV M, ROBERTS DR et al.: Unilateral left prefrontal transcranial magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by interleaved BOLD fMRI. Biol. Psychiatry (2001) 50(9):712-720.
168. TENEBACK CC, NAHAS Z, SPEER AM et al.: Changes in prefrontal cortex and paralimbic activity in depression following two weeks of daily left prefrontal TMS. J. Neuropsychiatry Clin. Neurosci. (1999) 11(4):426-435.
169. SPEER AM, WILLIS MW, HERSCOVITCH P et al.: Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with H215O positron emission tomography: II. Effects of prefrontal cortex rTMS. Biol. Psychiatry (2003) 54(8):826-832.
170. PESCHINA W, CONCA A, KONIG P, FRITZSCHE H, BERAUS W: Low frequency rTMS as an add-on antidepressive strategy: heterogeneous impact on 99mTc-HMPAO and 18 F-FDG uptake as measured simultaneously with the double isotope SPECT technique. Pilot study. Nucl. Med. Commun. (2001) 22(8):867-873.
171. LISANBY SH, LUBER B, SCHLAEPFER TE, SACKEIM HA: Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology (2003) 28(10):1852-1865.
172. KOSEL M, FRICK C, LISANBY SH, FISCH HU, SCHLAEPFER TE: Magnetic seizure therapy improves mood in refractory major depression. Neuropsychopharmacology (2003) 28(11):2045-2048.
173. WHITE PF, AMOS Q, ZHANG Y et al.: Anesthetic considerations for magnetic seizure therapy: a novel therapy for severe depression. Anesth. Analg. (2006) 103(1):76-80.
174. DEUSCHL G, WENZELBURGER R, KOPPER F, VOLKMANN J: Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a therapy approaching evidence-based standards. J. Neurol. (2003) 250(Suppl. 1):143-146.
175. MAYBERG HS, LOZANO AM, VOON V et al.: Deep brain stimulation for treatment-resistant depression. Neuron (2005) 45(5):651-660.
176. MAYBERG HS, LOZANO AM, VOON V et al.: Sustained response to chronic deep brain stimulation (DBS) of the subgenual cingulate region (Cg25) in treatment-resistant depression: 1 year follow-up, Program No. 678.17. Society for Neuroscience. Washington, D.C. 2005).
177. NUTTIN BJ, GABRIELS L, VAN KUYCK K, COSYNS P: Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive-compulsive disorder: anecdotal reports. Neurosurg. Clin. N. Am. (2003) 14(2):267-274.
178. GREENBERG B: Deep brain stimulation: clinical findings in OCD and depression. 59th Annual Meeting of the Society of Biological Pcychiatry. New York, NY (April 29-May 1 2004).
179. SCHLAEPFER TE, LIEB K: Deep brain stimulation for treatment of refractory depression. Lancet (2005) 366(9495):1420-1422.
180. MCINTYRE CC, SAVASTA M, KERKERIAN-LE GOFF L, VITEK JL: Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol (2004) 115(6):1239-1248.
181. BURNS RA, LOCK T, EDWARDS DR et al.: Predictors of response to amine-specific antidepressants. J. Affect. Disord. (1995) 35(3):97-106.
182. FAVA M, UEBELACKER LA, ALPERT JE et al.: Major depressive subtypes and treatment response. Biol. Psychiatry (1997) 42(7):568-576.
183. HEILIGENSTEIN JH, TOLLEFSON GD, FARIES DE: Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J. Affect. Disord. (1994) 30(3):163-173.
184. MCGRATH PJ, STEWART JW, HARRISON WM et al.: Predictive value of symptoms of atypical depression for differential drug treatment outcome. J. Clin. Psychopharmacol. (1992) 12(3):197-202.
185. JOYCE PR, MULDER RT, MCKENZIE JM, LUTY SE, CLONINGER CR: Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depress. Anxiety (2004) 19(3):180-186.
186. HOLTZHEIMER PE III, RUSSO J, CLAYPOOLE KH, ROY-BYRNE P, AVERY DH: Shorter duration of depressive episode may predict response to repetitive transcranial magnetic stimulation. Depress. Anxiety (2004) 19(1):24-30.
187. BRAKEMEIER EL, LUBORZEWSKI A, DANKER-HOPFE H, KATHMANN N, BAJBOUJ M: Positive predictors for antidepressive response to prefrontal repetitive transcranial magnetic stimulation (rTMS). J. Psychiatr. Res. (2006) (in press).
188. FRANK E, JARRETT DB, KUPFER DJ, GROCHOCINSKI VJ: Biological and clinical predictors of response in recurrent depression: a preliminary report. Psychiatry Res. (1984) 13(4):315-324.
189. RIBEIRO SC, TANDON R, GRUNHAUS L, GREDEN JF: The DST as a predictor of outcome in depression: a meta-analysis. Am. J. Psychiatry (1993) 150(11):1618-1629.
190. COPPEN A, MILLN P, HARWOOD J, WOOD K: Does the dexamethasone suppression test predict antidepressant treatment success? Br. J. Psychiatry (1985) 146:294-296.
191. LUTHRINGER R, MINOT R, TOUSSAINT M et al.: All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment. Biol. Psychiatry (1995) 38(2):98-104.
192. CASPI A, SUGDEN K, MOFFITT TE et al.: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science (2003) 301(5631):386-389.
193. KENDLER KS, KUHN JW, VITTUM J, PRESCOTT CA, RILEY B: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch. Gen. Psychiatry (2005) 62(5):529-535.
194. FRODL T, MEISENZAHL EM, ZILL P et al.: Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch. Gen. Psychiatry (2004) 61(2):177-183.
195. LEKWAUWA RE, MCQUOID DR, STEFFENS DC: Hippocampal volume as a predictor of short-term ECT outcomes in older patients with depression. Am. J. Geriatr. Psychiatry (2005) 13(10):910-913.
196. MAYBERG HS, BRANNAN SK, MAHURIN RK et al.: Cingulate function in depression: a potential predictor of treatment response. Neuroreport (1997) 8(4):1057-1061.
197. WU J, BUCHSBAUM MS, GILLIN JC et al.: Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am. J. Psychiatry (1999) 156(8):1149-1158.
198. DOUGHERTY DD, WEISS AP, COSGROVE GR et al.: Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J. Neurosurg. (2003) 99(6):1010-1017.
199. SEMINOWICZ DA, MAYBERG HS, MCINTOSH AR et al.: Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage (2004) 22(1):409-418.
200. PEZAWAS L, MEYER-LINDENBERG A, DRABANT EM et al.: 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat. Neurosci. (2005) 8(6):828-834.